Research That Matters
Cutting-edge science, translated. Get curated summaries of breakthrough research, emerging therapies, and scientific developments—with methodology critiques and clinical relevance assessments.
Start This BriefingWho This Is For
What Your Briefings Cover
Breakthrough Findings
High-impact papers from Nature, Cell, NEJM, and specialty journals. What's actually significant vs. hype.
Methodology Analysis
Critical evaluation of study design, sample sizes, and statistical approaches. Know when to trust results.
Emerging Therapies
Gene therapies, senolytics, microbiome interventions. What's in the pipeline and realistic timelines.
Translational Developments
From bench to bedside. Which research is moving toward clinical application and what barriers remain.
Sample Briefing Excerpt
"Rapamycin Derivatives for Aging: PEARL Trial Interim Analysis"
Study: PEARL (Phase 2, n=240) testing RTB101 (mTORC1 inhibitor) in adults 65+ for immune function and respiratory infection reduction.
Key findings:
- 20% reduction in respiratory infections vs. placebo (p=0.03)
- Improved influenza vaccine response (+40% antibody titers)
- No significant adverse events at tested doses
Methodology notes: Randomized, double-blind, placebo-controlled. Primary endpoint met. However, respiratory infection was self-reported (limitation). Dropout rate of 15% slightly above expected.
Significance: First rigorous evidence that mTOR modulation can improve immune function in older adults. If Phase 3 confirms, could be first FDA-approved "anti-aging" intervention targeting a fundamental aging pathway.
Timeline: Phase 3 enrollment expected 2025, results 2027-2028.